Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
13 p, 2.0 MB Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer / Garrido-Castro, Ana (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ; Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ; Guo, Hao (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Data Sciences) ; Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ; Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ; Gavilá, Joaquin (Fundació Institut Valencià d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paré Brunet, Laia (SOLTI Breast Cancer Research Group) ; Céliz, Pamela (SOLTI Breast Cancer Research Group) ; Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ; Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ; Savoie, Jennifer (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Xu, Zhan (Northern Arizona University. School of Communication) ; Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ; Krop, Ian E. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Solit, David B. (Memorial Sloan Kettering Cancer Center) ; Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ; Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ; Winer, Eric P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Lin, Nancy U. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ; Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.